【Objective】 To systematically evaluate the therapeutic efficacy of autologous platelet-rich plasma combined with negative pressure wound therapy on chronic refractory wounds, and to provide reference for clinical treatment. 【Methods】 Randomized controlled trials of autologous platelet-rich plasma combined with negative pressure wound therapy for the treatment of chronic refractory wounds were included in the databases of CNKI, Wan fang, VIP, PubMed, Embase and Cochrane Library from the time of database construction to November 2022. After literature screening, data extraction and quality evaluation, Meta analysis was performed using Stata 15.1 software. 【Results】 After screening, a total of 11 Chinese literatures that met the criteria of this paper were retrieved, involving a total of 359 patients with chronic refractory wounds. The observation group was treated with autologous platelet-rich plasma combined with negative pressure wound therapy, and the control group was treated with negative pressure wound therapy alone. Meta-analysis suggested that compared with negative pressure wound therapy alone, autologous platelet-rich plasma combined with negative pressure wound therapy shortened wound healing time [WMD=-6.08, 95%CI (-7.77, -4.40), P<0.05]. The hospitalization was shortened [WMD=-8.24, 95%CI (-11.55, -4.94), P<0.05], the pain score was decreased [WMD=-1.73, 95%CI (-2.06, -1.40), P<0.05], and the positive rate of bacterial culture on the wound was decreased [RR=0.28, 95%CI(0.16, 0.49), P<0.05], the wound treatment effect was good [RR=1.28, 95%CI(1.17, 1.41), P<0.05]. 【Conclusion】 Based on current studies, compared with the negative pressure wound therapy alone, autologous platelet-rich plasma combined with negative pressure wound therapy can effectively promote the healing of chronic refractory wounds, shorten the hospital stay, reduce pain and infection, and the clinical treatment effect is better.

【Objective】 To explore the mechanism of testosterone on eryptosis. 【Methods】 The erythrocyte suspension (1%) was cultured in vitro and divided into 3 groups: 2 kinds of eryptosis models induced by hydrogen peroxide (H2O2) in vitro, 3×10^-8 mol/L testosterone + 200 μmol/L H2O2 group (group A), 200 μmol/L H2O2 treatment group (group B) and 1×PBS buffer control group (group C). Erythrocytes were collected from 12 well plates (about 2×10⁶/well) at 24 h and 60 h to detect the eryptosis rate, intracellular ROS and [Ca²⁺ ]i through flow cytometry, and the changes of each index were analyzed by t test. 【Results】 The eryptosis rate(%)at 24 h and 60 h in group A, B and C were 2.61±0.28, 11.25±1.43 vs 7.15±0.95, 28.65±0.74 vs 1.32±0.07, 8.18±0.08 (P<0.01); ROS level(%): 14.52±0.68, 15.26±0.49 vs 16.68±0.60, 21.68±1.10 vs 7.61±0.21, 10.29±1.06 (P<0.01); [Ca²⁺ ]i(%): 6.54±0.46, 8.93±0.87 vs 11.78±0.76, 14.63±0.80 vs 1.36±0.20, 2.44±0.38 (P<0.01). The eryptosis rate, ROS level and [Ca^{2 +} ]i in group A were significantly lower than those in group B (P<0.01). 【Conclusion】 Testosterone effectively inhibits eryptosis induced by H2O2 in vitro and its mechanism may be related to reducing ROS production and maintaining normal [Ca²⁺ ]i.

Conventional therapies for hemophilia A (HA) are prophylactic or on-demand intravenous FVIII infusions. However, they are expensive and inconvenient to perform. Thus, better strategies for HA treatment must be developed. In this study, a recombinant FVIII cDNA encoding a human/rat hybrid FVIII with an enhanced procoagulant potential for adeno-associated virus (AAV)-delivered gene therapy was developed. Plasmids containing human FVIII heavy chain (hHC), human light chain (hLC), and rat light chain (rLC) were transfected into cells and hydrodynamically injected into HA mice. Purified AAV viruses were intravenously injected into HA mice at two doses. Results showed that the hHC + rLC protein had a higher activity than the hHC + hLC protein at comparable expression levels. The specific activity of hHC + rLC was about 4- to 8-fold higher than that of their counterparts. Hydrodynamic injection experiments obtained consistent results. Notably, the HA mice undergoing the AAV-delivered hHC + rLC treatment exhibited a visibly higher activity than those treated with hHC + hLC, and the therapeutic effects lasted for up to 40 weeks. In conclusion, the application of the hybrid FVIII (hHC + rLC) via an AAV-delivered gene therapy substantially improved the hemorrhagic diathesis of the HA mice. These data might be of help to the development of optimized FVIII expression cassette for HA gene therapy.
Animals ; Dependovirus/genetics* ; Factor VIII/metabolism* ; Genetic Therapy/methods* ; Hemophilia A/therapy* ; Humans ; Mice ; Rats